Rates of Prenatal Cannabis Use Among Pregnant Women Before and During the COVID-19 Pandemic
Kelly C. Young‐Wolff, G. Thomas Ray, Stacey Alexeeff, Sara R. Adams, Monique B. Does, Deborah Ansley, Lyndsay A. Avalos
Abstract
reflect several components of HR 3, including price negotiation, and Medicare vs national net prices may differ. The 52% discount is likely conservative due to data limitations, including use of net prices to manufacturers rather than to payers (including supply chain markups) and the absence of net price data for HR 3 countries. Furthermore, actual spending under HR 3 may be lower if Medicaid and other payers already face subinternational prices for some drugs. Although international reference pricing would yield considerable savings, other important considerations around the design and implementation of drug price regulation include incentives for research and development, industry launch and pricing strategies, and increasing utilization in response to lower prices.